Replimune (REPL) Long-Term Debt Issuances (2019 - 2023)

Replimune (REPL) reported Long-Term Debt Issuances of -$1.8 million for Q1 2023, down 620.0% sequentially from $355000.0 in Q4 2019.

Replimune (REPL) Long-Term Debt Issuances (2019 - 2023) Analysis & Trends

Replimune (REPL) has 2 years of Long-Term Debt Issuances data on file, last reported at -$1.8 million in Q1 2023.

For the quarter ending Q1 2023, Long-Term Debt Issuances changed N/A year-over-year to -$1.8 million; the trailing twelve-month figure through Mar 2025 stood at -$1.8 million (changed 0.0% YoY), and the FY2026 full-year result was $35.0 million, changed N/A from the prior year.
Long-Term Debt Issuances fell to -$1.8 million in Q1 2023, from $355000.0 in the prior quarter.
In the past five years, Long-Term Debt Issuances ranged from a high of $355000.0 in Q4 2019 to a low of -$1.8 million in Q1 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Replimune	970.73 Mn	970.73 Mn	-	-

Download Data